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doi:10.1016/j.jmii.2012.01.010Background: Over the past 20 years, Brevundimonas vesicularis has rarely been reported as
a pathogen causing human infection. The clinical manifestations of B. vesicularis bacteremia
and its susceptibility to antibiotics has not been characterized.
Methods: A retrospective study was conducted between 2006 and 2009 in a tertiary-care
hospital in southern Taiwan.
Results: A total of 22 cases of B. vesicularis bacteremia were identified during the study with
86% being community-acquired primary bloodstream infections. Of the 22 patients, 15 (68%)
presented with fever, fewer comorbidities, shorter hospital stays, lower mean creatinine
levels (1.10 mg/dL vs. 1.74 mg/dL), lower aspartate aminotransferase levels (29.1 IU/L vs.
79.0 IU/L), and lower alanine aminotransferase levels (16.4 IU/L vs. 67.0 IU/L) when compared
to afebrile patients. Among the bacterial isolates, 90.9% were susceptible to cefpirome, imi-
penem and piperacillin/tazobactam while 86.4% were susceptible to gentamicin, amikacin
and ciprofloxacin. However, 63.6% of the bacterial isolates were susceptible to ceftazidime,
and only 59.1% were susceptible to trimethoprim-sulfamethoxazole (TMP-SMX). The 30-day
mortality rate from all causes was 4.5%.
Conclusion: B. vesicularis is able to cause community-acquired and low-mortality primary
bloodstream infections. The resistance of B. vesicularis to trimethoprim-sulfamethoxazole
and ceftazidime limits the choice of available antibiotics for treatment.
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Brevundimonas vesicularis (formerly known as Pseudomonas
vesicularis), a non-fermenting Gram-negative bacillus,1,2
has been infrequently reported as a pathogen causing
hospital-acquired infection.3e5 Most cases of B. vesicularis
infection are community-acquired.4,6e11 B. vesicularis can
be isolated from the human endocervix, natural soil envi-
ronments, bottled water, and hospital environments
including shower hoses, dental unit reservoirs and hydro-
therapy pools.12e15 B. vesicularis can cause arthritis, endo-
carditis, meningitis, peritonitis, and primary bloodstream
infection in immunocompromised as well as immunocom-
petent patients.3e11 Whether B. vesicularis causes severe
morbidity or mortality remains unclear.
In this report, 22 cases of B. vesicularis primary
bacteremia were identified in a tertiary-care hospital in
southern Taiwan between 2006 and 2009. Trends of
increasing number of episodes, diversity, and prognosis of
B. vesicularis primary bacteremia were observed.
Materials and methods
Study design
From January 2006 to December 2009, the database of the
Clinical Microbiology Laboratory of Chi-Mei Medical Center
was reviewed to identify bacterial cultures from blood
specimens positive for B. vesicularis at the 1330-bed
tertiary-care hospital, which serves two million people in
southern Taiwan. This study was approved by the institu-
tional review board of Chi-Mei hospital (IRB No. 10006-007).
A patient was considered to have B. vesicularis bacteremia
when the bacteria was isolated from one or more separate
blood cultures processed by the BACTEC FX system (Becton
Dickinson, Sparks, MD, USA) and the patient presented with
compatible clinical symptoms. All patients with manifes-
tations of systemic inflammatory response syndrome (SIRS)
were routinely subject to aerobic and anaerobic blood
cultures with 7-day incubations before being reported as
negative for B. vesicularis. SIRS was defined as a patient
meeting any two of the following criteria: body tempera-
ture less than 36C or greater than 38C, heart rate greater
than 90 beats per minute, tachypnea with more than 20
breaths per minute, arterial partial pressure of carbon
dioxide less than 32 mmHg, white blood cell count less than
4000 cells/mm3 (4 x 109 cells/L) or greater than 12,000
cells/mm3 (12 x 109 cells/L); or the presence of greater
than 10% immature neutrophils (band forms).16 Patients
with positive B. vesicularis bacteremia were included in the
study with the exception of patients with polymicrobial
bacteremia. Identification of B. vesicularis was performed
using the APE 20 NE system (bioMe´rieux, Marcy L’etoile,
France) or Phoenix-100 ID/AST (Becton Dickinson) auto-
mated system. All of the B. vesicularis isolates were tested
for minimal inhibitory concentrations (MICs) by the agar
dilution method according to the guidelines of the Clinical
and Laboratory Standards Institute (CLSI).17 We used
Staphylococcus aureus (ATCC29213), Enterococcus faeca-
lis (ATCC29212), Escherichia coli (ATCC25922) and
Pseudomonas aeruginosa (ATCC27853) as quality controlstrains. Medical records were reviewed for demographic
data, clinical manifestations, co-morbidities, antibiotic
regimen and clinical outcomes.
Definitions
Primary bacteremia was defined as infection not specific to
an anatomical site. A nosocomial infection was defined as
any episode occurring >48 hours after hospitalization or
<14 days after previous discharge. A community-acquired
infection was defined as any episode occurring <48 hours
after hospitalization or >14 days after previous discharge.
Fever was defined as body temperature >37.8C. The
primary outcome was defined as 30-day all-cause mortality
and co-morbidities were obtained from medical records.
Inappropriate antibiotic therapy was defined as treatment
that did not include an antibiotic agent active against
B vesicularis, as determined by the in vitro agar dilution
method given during the 48 hours after the identification
of B. vesicularis.
Statistical analysis
Mean  standard deviation (SD) was calculated for each
continuous variable and percentages were calculated for
categorical variables. Categorical variables were evaluated
using the Fisher’s exact test and continuous variables were
evaluated using the ManneWhitney U test. A p value <0.05
was defined as statistically significant. All statistical analyses
wereperformedusingversion17of theStatistical Package for
the Social Sciences forWindows (SPSS Inc., Chicago, IL, USA).
Results
A total of 22 patients with B. vesicularis bacteremia were
recruited during the study period (Table 1). The ratio of
males to females was 0.83. The age of the patients ranged
from 3 to 94 years, with an average of 62.7 years; 13.6%
(3/22) of patients were younger than 20 years, whereas 50%
(11/22) were older than 70 years. Of the 15 patients with
underlying chronic illnesses, 31.8% (7/22) had hyperten-
sion, 22.7% had prior histories of stroke, and 18.2% (4/22)
had malignancies. In total, 13.6% (3/22) of B. vesicularis
bacteremia cases were healthcare-associated. The all-
cause mortality rate was 4.5% (1/22). The only death was
a 93-year-old female patient who acquired the bacteremia
after admission, presented with shock and then passed
away on day 24 of hospitalization. She had been treated
with ceftazidime and the isolate from her blood culture was
susceptible to ceftazidime [minimal inhibitory concentra-
tion (MIC)Z 4 mg/L]. Out of 22 patients, 15 presented with
fever at admission and these patients had fewer co-
morbidities when compared to afebrile patients (1 vs.
2.6, p Z 0.009). Laboratory analysis showed that febrile
patients had lower levels of creatinine (1.10 mg/dL vs.
1.74 mg/dL), aspartate aminotransferase (29.1 IU/L vs.
79.0 IU/L), and alanine aminotransferase (16.4 IU/L
vs. 67.0 IU/L) than afebrile patients (Table 2).
The length of hospital stay averaged 13.3 days for the 19
hospitalized patients (Table 3). Patients who had 3 or more
underlying diseases stayed longer than those who had 2 or
Table 1 Demographic characteristics and initial manifestations of 22 patients with B. vesicularis bacteremia
Case Gender Age Initial manifestation Co-morbidity Acquired source
1 F 78 Fever HTN Community
2 F 78 Abdominal pain HTN, LC, CKD Community
3 M 3 Fever Nil Community
4 M 55 Fever Alcoholism Hospital
5 F 93 Shock CHF CKD Hospital
6 F 32 Fever Nil Community
7 F 84 Fever HTN, old CVA Community
8 F 19 Fever Nil Community
9 M 48 Altered consciousness Old CVA, HTN, CHF Community
10 F 94 Shock Uterine prolapse Community
11 F 82 Altered consciousness HTN, old CVA, Malignancy Community
12 M 51 Fever Nil Community
13 F 74 Fever HTN, old CVA, Parkinsonism Community
14 M 78 Fever COPD, old CVA Hospital
15 F 69 Fever Malignancy Community
16 M 68 Abdominal pain Nil Community
17 M 76 Fever Malignancy, CKD Community
18 M 81 Respiratory distress HTN, DM, Parkinsonism Community
19 M 58 Fever Malignancy Community
20 F 7 Fever Nil Community
21 F 63 Fever Nil Community
22 M 75 Fever Parkinsonism Community
CHFZ congestive heart failure; CKDZ chronic kidney disease; COPDZ chronic obstructive pulmonary disease; CVAZ cerebral vascular
accident; DM Z diabetes mellitus; F Z female; HTN Z hypertension; LC Z liver cirrhosis; M Z male; Nil Z no known underlying
disease.
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initially afebrile had longer hospital stays than those who
were febrile (17.6 days vs. 8.2 days, p Z 0.043) (Table 2).Table 2 Comparison of demographic characteristics,
laboratory data, and length of hospital stay between pyretic
and apyretic patients
Pyretic Apyretic p
No. of patients (%) 15 (68.2) 7 (31.8)
Age (y) 54.8 77.7 0.052
No. of co-morbidities 1 2.57 0.009*
LOS (d) 8.2 17.6 0.043*
Laboratory data
WBC (cells/mL) 10600 9728 0.633
Hb (g/dL) 12.1 11.1 0.306
Platelets (103 cells/mL) 248 209 0.363
CRP (mg/L) 84.9 23.4 0.347
Naþ (mEq/L) 132 126 0.224
Kþ (mEq/L) 4.01 4.47 0.329
BUN (mg/dL) 25.7 42.4 0.114
Cr (mg/dL) 1.10 1.74 0.025*
AST (IU/L) 29.1 79.0 0.038*
ALT (IU/L) 16.4 67.0 0.021*
*p < 0.05.
ALT Z alanine aminotransferase; AST Z aspartate amino-
transferase; BUN Z blood urea nitrogen; Cr Z creatinine;
CRP Z C-reactive protein; Hb Z hemoglobin; LOS Z length of
hospital stay; WBC Z white blood cell.Antimicrobial susceptibility tests revealed that 90.9% of
B. vesicularis isolates were susceptible to cefpirome, imi-
penem and piperacillin/tazobactam, 86.4% were suscep-
tible to gentamicin, amikacin and ciprofloxacin, 63.6%
were susceptible to ceftazidime and only 59.1% were
susceptible to trimethoprim-sulfamethoxazole (Table 4).
40.9% (9/22) of the patients had been treated with anti-
biotics for other infections within the previous year; in
each case, cephalosporins consisting of cefazolin, cefur-
oxime and cefpirome were prescribed. However, the
antibiogram and length of stay were not statistically
different between those who were previously exposed to
cephalosporins and those who were not (9.5 days vs. 13.7
days, p Z 0.357) (Table 3).
Patients with B. vesicularis bacteremia received diverse
antibiotic regimens. Most patients were treated with
cephalosporins (12/22, 54.5%) but aminopenicillin with or
without beta-lactamase inhibitor (ampicillin or amoxicillin-
clavulanate), ureidopenicillin (piperacillin) or carbapenem
(ertapenem) were also given. Of the 22 patients, 10 (45.5%)
received inappropriate initial antibiotic therapy but there
was no significant difference in length of hospital stay (11
days vs. 10 days). Most of the patients recovered from the
infection and those who did not recover from infection
received an intravenous antibiotic regimen (Table 3).
Discussion
B. vesicularis bacteremia is a clinical challenge for physi-
cians due to a general lack of clinical experience within the
medical community.3e11,18 In this report, we described
Table 3 Summary of length of hospital stay, treatment regimen, treatment duration, antibiotic exposure within previous year,
and outcome
Case Previous antibiotic
exposure
Antibiotic regimen Hospital
stay (d)
Treatment
duration (d)
Outcome
1 N Cefazolin 4 4 Survival
2 N Cefazolin 14 8 Survival
3 N Cefazolin 0 0 Survival
4 Cefuroxime Clindamycin 6 5 Survival
5 N Ceftazidime 24 10 Death
6 N Gentamicin þ Metronidazole 4 8 Survival
7 Cefazolin Cefazolin/Cefpirome 10 5/5 Survival
8 Cefazolin Cefazolin 0 0 Survival
9 Cefazolin Ampicillin 40 23 Survival
10 N Cefpirome 15 8 Survival
11 N Piperacillin/Cefazolin 19 3/15 Survival
12 Cefazolin Cephalexin 0 0 Survival
13 N Ertapenem 10 8 Survival
14 N Ceftazidime 7 7 Survival
15 N Ceftazidime 7 6 Survival
16 N Cefpirome þ Metronidazole 6 4 Survival
17 Cefazolin Ciprofloxacin 16 10 Survival
18 N Cefazolin 5 4 Survival
19 Cefpirome Amoxicllin-clavulanate/Cefpirome 33 8/11 Survival
20 N Cephalexin 0 0 Survival
21 Cefazolin Ciprofloxacin þ clindamycin 8 8 Survival
22 Cefazolin Amoxicllin-clavulanate/Ceftazidime þ minocycline 10 8/8 Survival
N Z no previous antibiotic exposure history; Nil Z no antibiotic treatment.
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being community-acquired. One-third of our patients were
well prior to admission, in accordance with previous reports
suggesting that B. vesicularis is able to cause invasive
infections in healthy persons. However, the majority of
patients in this study had chronic diseases such as hyper-
tension, stroke and malignancy.
This report indicates that two-thirds of patients pre-
sented with fever at admission. Compared to afebrile
patients, febrile patients had fewer comorbidities, shorter
lengths of hospital stay, and lower levels of creatinine,
AST, and ALT. These differences suggest that fever may
serve as an important clinical clue for earlier diagnosis,
empiric antibiotic therapy, and may contribute to a posi-
tive outcome.Table 4 Antimicrobial susceptibility of Brevundimonas vesicula
Antimicrobial agent(s)
Range of MIC
Ceftazidime 0.125e>128
Cefpirome 0.03125e128
Piperacillin with tazobactam 0.25/4e256/4
Imipenem 0.125e64
Ciprofloxacin <0.015625e64
Gentamicin 1e>64
Amikacin 2e>512
Trimethoprim with sulfamethoxazole 0.25/4.75e>32/608
MIC50Z minimum concentration required to inhibit the growth of 50%
inhibit the growth of 90% of microorganisms.This case series also consisted largely of patients with
primary bloodstream infection without other associated
infectious foci. B. vesicularis was not isolated from urine,
sputum or pus specimens which may be explained by
a higher rate of blood invasion by B. vesicularis or a reduced
ability of the pathogen to compete with other bacterial
flora. Further research is needed to clarify this issue. Both
the favorable outcome (i.e., only one mortality) and the
lack of significant prolonged hospital stays, even for those
patients without appropriate initial empirical antibiotic
therapy, indicated the low virulence for B. vesicularis.
The antibiotic susceptibility tests of the B. vesicularis
isolates revealed that more than 90% were susceptible to
cefpirome, piperacillin/tazobactam, and carbapenems,
followed by aminoglycosides and ciprofloxacin. By contrast,ris isolates using the agar dilution method
MICs (mg/L) Number (%) of
susceptible isolatesMIC50 MIC90
2 32 14 (63.6)
0.125 4 20 (90.9)
4 16 20 (90.9)
0.125 2 20 (90.9)
0.25 4 19 (86.4)
1 16 19 (86.4)
2 16 19 (86.4)
0.5/9.5 >32/608 13 (59.1)
of microorganisms; MIC90 Z minimum concentration required to
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trimethoprim-sulfamethoxazole (Table 4). A review of
literature revealed antibiograms for B. vesicularis con-
ducted only on a single or a few strains based on the Kerby-
Bauer diffusion method without the application of updated
CLSI guidelines.3,4,7,8,11,17 Compared with a recently pub-
lished article, B. vesicularis isolates are 100% sensitive to
piperacillin/tazobactam and amikacin but only 27% and 3%
sensitive to cefepime and ceftazidime, respectively, based
on MICs obtained by the agar dilution method.19 Therefore,
piperacillin/tazobactam, imipenem, and cefpirome are
suggested for the treatment of B. vesicularis infection.
Our study had several limitations. The study was retro-
spective and conducted in a single tertiary hospital serving
a population of two million. There were an inadequate
number of patients to draw broad conclusions from and no
information obtained from long-term care facilities.
However, to the best of our knowledge, B. vesicularis
infection has been reported only rarely in the published
literature. Therefore, we can conclude that B. vesicularis
causes community-acquired and low-mortality bloodstream
infections, and that the resistance of this microorganism to
trimethoprim-sulfamethoxazole and ceftazidime limits the
choice of antibiotics for its management.
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